Chris Bond

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

M. Fischer, J. Lewicki, A. Gurney, 2012, Proceedings of the National Academy of Sciences.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin

K. Wiedemeyer, M. Köbel, B. Gilks, 2020, Journal for ImmunoTherapy of Cancer.

Deconvolution of clinical variance in CAR-T cell pharmacology and response

D. Kirouac, P. Zandstra, C. Zmurchok, 2023, Nature Biotechnology.

Development of JCARH125: Optimization of a Fully Human Anti-Bcma CAR for Use in the Treatment of Multiple Myeloma

C. Liu, Jon C Jones, R. Brentjens, 2017 .

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .